Hector Tamez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10565900/publications.pdf

Version: 2024-02-01

47 papers	5,244 citations	257101 24 h-index	264894 42 g-index
47 all docs	47 docs citations	47 times ranked	6473 citing authors

#	Article	IF	Citations
1	Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings From the EXTEND-DAPT Study. Circulation, 2022, 145, 97-106.	1.6	20
2	Predicting Residual Angina After Chronic Total Occlusion Percutaneous Coronary Intervention: Insights from the OPENâ€CTO Registry. Journal of the American Heart Association, 2022, 11, e024056.	1.6	5
3	Comparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006589.	0.9	20
4	Long-term outcomes of percutaneous coronary intervention for in-stent restenosis among Medicare beneficiaries. EuroIntervention, 2021, 17, e380-e387.	1.4	32
5	The Impact of Peripheral Artery Disease in Chronic Total Occlusion Percutaneous Coronary Intervention (Insights From PROGRESS-CTO Registry). Angiology, 2020, 71, 274-280.	0.8	6
6	Impact of adherence to the hybrid algorithm for initial crossing strategy selection in chronic total occlusion percutaneous coronary intervention. Revista Espanola De Cardiologia (English Ed), 2020, 74, 1023-1031.	0.4	1
7	Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. Circulation, 2020, 142, 306-308.	1.6	8
8	Use of Administrative Claims to Assess Outcomes and Treatment Effect in Randomized Clinical Trials for Transcatheter Aortic Valve Replacement. Circulation, 2020, 142, 203-213.	1.6	23
9	Retrograde Chronic Total Occlusion Percutaneous Coronary Intervention viaÂSaphenous Vein Graft. JACC: Cardiovascular Interventions, 2020, 13, 517-526.	1.1	21
10	Validating the use of registries and claims data to support randomized trials: Rationale and design of the Extending Trial-Based Evaluations of Medical Therapies Using Novel Sources of Data (EXTEND) Study. American Heart Journal, 2019, 212, 64-71.	1.2	23
11	Depression and Angina Among Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2019, 12, 651-658.	1.1	19
12	Comparison of Clinical Trials and Administrative Claims to Identify Stroke Among Patients Undergoing Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2019, 12, e008231.	1.4	17
13	Contemporary Use and Trends in Unprotected Left Main Coronary Artery Percutaneous Coronary Intervention in the United States. JAMA Cardiology, 2019, 4, 100.	3.0	45
14	Association of Physician Variation in Use of Manual Aspiration Thrombectomy With Outcomes Following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. JAMA Cardiology, 2019, 4, 110.	3.0	26
15	Effect of Short Procedural Duration With Bivalirudin on Increased Risk of Acute Stent Thrombosis in Patients With STEMI. JAMA Cardiology, 2017, 2, 673.	3.0	6
16	Type 4a myocardial infarction: Incidence, risk factors, and longâ€term outcomes. Catheterization and Cardiovascular Interventions, 2017, 89, 849-856.	0.7	23
17	Procedure Logging in Interventional Cardiology Training Curriculum. Journal of the American College of Cardiology, 2016, 67, 2798-2801.	1.2	1
18	Serum phospholipid fraction of polyunsaturated fatty acids is the preferred indicator for nutrition and health status in hemodialysis patients. Journal of Nutritional Biochemistry, 2016, 38, 18-24.	1.9	2

#	Article	IF	Citations
19	African Americans with left ventricular hypertrophy and chronic kidney disease: what should we do?. Nephrology Dialysis Transplantation, 2016, 31, 1969-1970.	0.4	0
20	Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia. Journal of the American Society of Nephrology: JASN, 2016, 27, 903-913.	3.0	213
21	Prognosis of Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis: A Prospective Cohort Study. International Journal of Nephrology, 2015, 2015, 1-9.	0.7	66
22	Nutritional Vitamin D Supplementation in Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 611-619.	2.2	69
23	Vitamin D and Its Effects on the Heart. , 2015, , 107-116.		0
24	Vitamin D and chronic kidney diseaseâ€“mineral bone disease (CKDâ€“MBD). BoneKEy Reports, 2014, 3, 498.	2.7	55
25	Vitamin Dâ€“Binding Protein and Vitamin D Status of Black Americans and White Americans. New England Journal of Medicine, 2013, 369, 1991-2000.	13.9	898
26	Reply to â€œThe role of fibroblast growth factor-23 in left atrial volumeâ€• American Heart Journal, 2013, 165, e23.	1.2	1
27	Inverse relationship between long-chain n-3 fatty acids and risk of sudden cardiac death in patients starting hemodialysis. Kidney International, 2013, 83, 1130-1135.	2.6	45
28	Impact of new vitamin D data on future studies and treatment. Current Opinion in Nephrology and Hypertension, 2013, 22, 377-382.	1.0	7
29	Does vitamin D modulate blood pressure?. Current Opinion in Nephrology and Hypertension, 2013, 22, 204-209.	1.0	53
30	Carbamylation of Serum Albumin and Erythropoietin Resistance in End Stage Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1927-1934.	2.2	37
31	Active Vitamin D Treatment for Reduction of Residual Proteinuria. Journal of the American Society of Nephrology: JASN, 2013, 24, 1863-1871.	3.0	126
32	Fatty Acids and Other Risk Factors for Sudden Cardiac Death in Patients Starting Hemodialysis. American Journal of Nephrology, 2013, 38, 12-18.	1.4	24
33	Phospholipid PUFA: a better indicator for assessing health risks. FASEB Journal, 2013, 27, 1072.16.	0.2	0
34	Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney Disease. JAMA - Journal of the American Medical Association, 2012, 307, 674.	3.8	495
35	Vitamin D and hypertension. Current Opinion in Nephrology and Hypertension, 2012, 21, 492-499.	1.0	37
36	Low Blood Levels of Long-Chain nâ€“3 Polyunsaturated Fatty Acids in US Hemodialysis Patients: Clinical Implications. American Journal of Nephrology, 2012, 36, 451-458.	1.4	34

#	Article	IF	Citations
37	Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. American Heart Journal, 2012, 164, 902-909.e2.	1.2	112
38	Soluble Erythropoietin Receptor Contributes to Erythropoietin Resistance in End-Stage Renal Disease. PLoS ONE, 2010, 5, e9246.	1.1	43
39	Role of Vitamin D and Vitamin D Analogs for Bone Health and Survival in Chronic Kidney Disease. , 2010, , 955-965.		0
40	Low Plasma Level of Cathelicidin Antimicrobial Peptide (hCAP18) Predicts Increased Infectious Disease Mortality in Patients Undergoing Hemodialysis. Clinical Infectious Diseases, 2009, 48, 418-424.	2.9	131
41	Plasma Gelsolin and Circulating Actin Correlate with Hemodialysis Mortality. Journal of the American Society of Nephrology: JASN, 2009, 20, 1140-1148.	3.0	98
42	Phosphorus Binders and Survival on Hemodialysis. Journal of the American Society of Nephrology: JASN, 2009, 20, 388-396.	3.0	341
43	Reply to DiNubile. Clinical Infectious Diseases, 2009, 49, 164-165.	2.9	0
44	Klotho Variants and Chronic Hemodialysis Mortality. Journal of Bone and Mineral Research, 2009, 24, 1847-1855.	3.1	54
45	Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis. New England Journal of Medicine, 2008, 359, 584-592.	13.9	1,546
46	Impact of Activated Vitamin D and Race on Survival among Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2008, 19, 1379-1388.	3.0	156
47	Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 16810-16815.	3.3	305